ENTA—Mavyret’s US new-patient share=55.2%—the highest-ever weekly figure—in the week ending 11/30/18, as reported by IMS. GILD’s US new-patient share was 44.2%, and MRK’s was 0.6%%.
Mavyret’s US total-script share was 48.3%, also the highest-ever weekly figure, as reported by IMS. GILD’s US total-script share was 50.9%, and MRK’s was 0.8%.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”